Targeted alpha therapy using Radium-223: From physics to biological effects
- 1 July 2018
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 68, 47-54
Abstract
No abstract availableKeywords
Funding Information
- Foundation for Science and Technology (UID/NEU/04539/2013)
- FEDER-COMPETE (POCI-01-0145-FEDER-007440)
This publication has 59 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone MetastasesClinical Genitourinary Cancer, 2013
- Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone diseaseCancer Management and Research, 2013
- Cancer and Radiation Therapy: Current Advances and Future DirectionsInternational Journal of Medical Sciences, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Radiation Resistance of Cancer Stem Cells: The 4 R's of Radiobiology RevisitedStem Cells, 2010
- Alpha-particles for targeted therapyAdvanced Drug Delivery Reviews, 2008
- Therapeutic Radionuclides: Biophysical and Radiobiologic PrinciplesSeminars in Nuclear Medicine, 2008
- Osteoblasts in prostate cancer metastasis to boneNature Reviews Cancer, 2005
- The Hallmarks of CancerCell, 2000